Article

Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).

2022-06-13

Abstract excerpt

<title>Abstract</title> <p><bold>Background</bold>: The 2020 pandemic of SARS-CoV-2 causing COVID-19 disease is an unprecedented global emergency. COVID-19 appears to be a disease with an early phase where the virus replicates, coinciding with first presentation of symptoms, followed by a later ‘inflammatory’ phase which results in severe disease in some individuals. It is known from other rapidly progressive inf...

Topics

Open a Topic to create a Post that cites this publication.

Identifiers and source

Literature Corpus work: 45cb9b83-cea4-50f5-81e0-94ea390785fe
DOI: 10.21203/rs.3.rs-1273552/v1

Open publication

Related research

Semantic proximity does not establish scientific evidence.

Click a neighbor to travelStep 1 · 12 closest

Favipiravir and/or Nitazoxanide: a randomized, double-blind, 2x2 design, placebo-controlled trial of early therapy in COVID-19 (FANTAZE).DOI 10.21203/rs.3.rs-1273552/v1Read

Comparative efficacy and safety of current drugs against COVID-19: A systematic review and network meta-analysisSemantic proximity Read

Early use of nitazoxanide in mild Covid-19 disease: randomized, placebo-controlled trialSemantic proximity Read

Tixagevimab-cilgavimab (AZD7442) for the treatment of patients hospitalized with COVID-19 (DisCoVeRy): A phase 3, randomized, double-blind, placebo-controlled trialSemantic proximity Read

A Proposed Randomized, Double Blind, Placebo Controlled Study Evaluating Doxycycline for the Prevention of COVID-19 Infection and Disease In Healthcare Workers with Ongoing High Risk Exposure to COVID-19Semantic proximity Read

A snapshot of the ongoing clinical research on COVID-19Semantic proximity Read

Bromhexine, for Post Exposure COVID-19 Prophylaxis: A Randomized, Double-Blind, Placebo Control TrialSemantic proximity Read

REGEN-COV Antibody Combination in Outpatients With COVID-19 – Phase 1/2 ResultsSemantic proximity Read

REGEN-COV Antibody Cocktail Clinical Outcomes Study in Covid-19 OutpatientsSemantic proximity Read

Sofosbuvir/ledipasvir in combination or nitazoxanide alone are safe and efficient treatments for COVID-19 infection: A randomized controlled trial for repurposing antivirals.Semantic proximity Read

A Randomized, Controlled Study on the Safety and Efficacy of Maraviroc and/or Favipiravir Vs Currently Used Therapy in Severe COVID-19 Adults. (COMVIVIR, clinicaltrials.gov NCT04475991)Semantic proximity Read

Outpatient Treatment of COVID-19 and the Development of Long COVID Over 10 Months: A Multi-Center, Quadruple-Blind, Parallel Group Randomized Phase 3 TrialSemantic proximity Read

Randomized controlled trials do not support efficacy of any of the tested doses of fluvoxamine in prevention of disease progression in adults with incipient non-severe COVID-19 disease: a case-study systematic review and meta-analysisSemantic proximity Read